AzTrials
AzTrials

COVID19NCT04394000

Impact of an Intensified Thromboprofylaxis Protocol in COVID-19

An observational study of COVID19 and Thromboembolism, run by Jessa Hospital at 1 site in Belgium.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
COVID19, Thromboembolism
What is being tested?
thromboprofylaxis protocol and standard protocol
How many people
72 participants
Where
1 siteBelgium
Study dates
4 May 2020to 15 May 2020
How long will I take part?
1 Month
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Adult, Older adult

Study population: All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Who may be able to join

  • All adult COVID19+ patients admitted to the ICU from 13th of March until 20th of April 2020.

Who cannot join

  • Patients younger than 18 years old.

Trial locations and contacts

1 site in 1 country.

Belgium1 site
  • Jessa hospital

    Hasselt, 3500

Other trials in Belgium

About this study

Official title: Impact of Implementation of an Intensified Thromboprofylaxis Protocol in in Critically Ill ICU Patients With COVID-19: a Longitudinal Controlled Before-after Study

The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Read the detailed description

Background Patients admitted to the Intensive Care Unit (ICU) are known to be at risk for thrombo-embolic events. Virchow's triad describes the major risk factors in three categories: venous stasis, vessel injury and activation of blood coagulation. A prolonged mechanical ventilation together with the hemodynamic effects of this ventilation with a high positive and expiratory pressure (PEEP), the presence of central venous catheters, the immobilization of these patients and the presence of obesity or other comorbidities can attribute to the occurrence of a deep venous thrombosis (DVT) in patients admitted at ICU. The incidence of DVT during ICU stay has been reported between 5 and 15%.

On the 13th of March, the first COVID-19 patient was admitted at the ICU at the Jessa Hospital. Within a few days, the admissions at our COVID-19 unit grew exponential. In these difficult time, research concerning COVID-19 has been performed indicating the COVID-19 virus induces a hyper-inflammatory state. It has been suggested that systemic inflammation induces endothelial injury. This will activate the coagulation cascade and impair fibrinolysis with disruption of endothelial barrier, and loss of physiologic antithrombotic factors which may elevated the risk for DVTs significantly. Up to now, there is still no causal treatment for COVID-19. The current management of COVID-19 is mainly supportive i.e. a prolonged inflammatory status and a prolonged risk for VTE.

We have shown in a previous cross sectional study that the prevalence of deep venous thrombosis (DVT) in critically ill ICU patients with COVID-19 treated with a prophylactic dose of low molecular weight heparin (LMWH) is more than 60% (submitted manuscript). Consequently, the risk of VTE complications in this patient group is very high. In the light of these findings, an intensified thromboprofylaxis protocol was applied in critically ill ICU patients with COVID-19 at our ICU units since 31st of March 2020.

Aim The aim of this study is to investigate and compare the mortality, the incidence of DVT and the incidence of kidney and liver failure in patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol on 31st of March 2020. Patients in the before group are admitted at the ICU from 13/3/2020-30/3/2020 and patients in the after group are admitted to the ICU from 31/3 until 20/4/2020.

Design This is a retrospective, longitudinal, before-after controlled study investigating the mortality, the incidence of DVT and the incidence of kidney and liver failure in COVID-19 patients admitted to the ICU before and after the implementation of an intensified thromboprofylaxis protocol.

Outcome measures The primary endpoint of this retrospective study is to investigate the mortality in critically ill ICU patients before and after the implementation of the intensified thromboprofylaxis protocol in our hospital.

Secondary endpoints are the incidence of DVTs with the number and locations of these thromboses, the incidence of kidney failure and the incidence of liver failure in COVID-19 patients admitted to the ICU before and after the implementation of the thromboprofylaxis protocol.

Additional data collection

Additional collected parameters are listed below and are collected as a standard-of-care in our hospital:

  • Demographics: i.e age, gender, BMI, Apache II score (to predict mortality)
  • Comorbidities: smoking, obesity, hypertension, diabetes, cardiovascular disease, respiratory disease, malignancies, renal failure (AKI), liver failure, gastrointestinal disease, neurological conditions, mental state, other
  • Symptoms at the time of admission to ICU: i.e fever, body temperature, dyspnoea, headache, diarrhea etc…
  • Laboratory results of all standard parameters measured
  • Treatment: antiviral agents, antibiotics, etc…
  • Complications: shock, heart failure, sepsis, stroke, etc…
  • Ventilation: method, PEEP, FiO2, P/F ratio ..
  • SOFA score (Sequential Organ Failure Assessment)
  • Radiological findings: pneumonia, ground-glass opacity..
Being tested
thromboprofylaxis protocol, standard protocol
Medical subject headings
COVID-19, Thromboembolism

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • thromboprofylaxis protocolOther

    This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity

  • standard protocolOther

    This protocol contains a routine low dose pharmacological venous thromboembolism (VTE) prophylaxis with LMWH

Study groups in NCT04394000
Study groupRoleWhat they receive
Before or control groupAll patients admitted to ICU from March 13th 2020 until March 30th 2020 received routine low dose pharmacological VTE prophylaxis
Receives: Other: standard protocol
After or intervention groupOn March 31th 2020 an individualised, more aggressive thromboprophylaxis protocol was implemented. This individualised protocol contains three cornerstones: an increase in dosage of prophylactic LMWH close to therapeutic doses, introduction of routine venous ultrasonography and daily measurements of plasma anti-factor Xa activity
Receives: Other: thromboprofylaxis protocol

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 2 week mortality

    mortality was assessed in all COVID 19 patients admitted to the ICU

    Measured: 2 weeks after admission at ICU

Secondary outcomes (12)
  1. incidence of venous thromboembolism

    the incidence of venous thromboembolism was evaluated in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  2. 1 week mortality

    mortality was assessed in all COVID 19 patients admitted to the ICU

    Measured: 1 week after admission at ICU

  3. 3 week mortality

    mortality was assessed in all COVID 19 patients admitted to the ICU

    Measured: 3 weeks after admission at ICU

  4. 1 month mortality

    mortality was assessed in all COVID 19 patients admitted to the ICU

    Measured: 1 month after admission at ICU

  5. incidence of kidney failure

    incidence of acute kidney failure in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  6. incidence of continuous renal replacement therapy (CRRT)

    incidence of continuous renal replacement therapy (CRRT) in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  7. lowest PaO2/FiO2 (P/F) ratio

    evaluation of the lowest P/F ratio in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  8. highest Sequential Organ Failure Assessment (SOFA) score

    evaluation of the highest SOFA score in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  9. length of stay

    evaluation of the length of stay in ICU and hospital of all COVID 19 patients admitted to the ICU

    Measured: during ICU and hospital stay up till 3th of May 2020

  10. highest bilirubin

    evaluation of the highest bilirubine level in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  11. highest ( AST

    evaluation of the highest AST level in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

  12. highest Aspartaat-Amino-Transferase (ALT)

    evaluation of the highest ALT level in all COVID 19 patients admitted to the ICU

    Measured: during ICU stay up till 3th of May 2020

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted19 May 2020
  2. Study start4 May 2020
  3. Primary completion15 May 2020
  4. Study completion15 May 2020

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Other
Enrolment
72 participants (actual)
Target duration
1 Month
IDs, dates and publications
ClinicalTrials.gov ID
NCT04394000
Sponsor's protocol ID
Jessa_20.48
Status last verified
May 2020
First submitted
16 May 2020
Last updated
19 May 2020
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Stessel B, Vanvuchelen C, Bruckers L, Geebelen L, Callebaut I, Vandenbrande J, Pellens B, Van Tornout M, Ory JP, van Halem K, Messiaen P, Herbots L, Ramaekers D, Dubois J. Impact of implementation of an individualised thromboprophylaxis protocol in critically ill ICU patients with COVID-19: A longitudinal controlled before-after study. Thromb Res. 2020 Oct;194:209-215. doi: 10.1016/j.thromres.2020.07.038. Epub 2020 Jul 22.

    PubMed 32788120

Questions about this trial

What is this clinical trial studying?

An observational study of COVID19 and Thromboembolism, run by Jessa Hospital at 1 site in Belgium.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 19 May 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Belgium. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

2 week mortality (time frame: 2 weeks after admission at ICU). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04394000, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 19 May 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in